Immunovant (NASDAQ:IMVT) CEO Sells $342,918.90 in Stock

Immunovant, Inc. (NASDAQ:IMVT) CEO Eric Venker sold 14,229 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $24.10, for a total transaction of $342,918.90. Following the sale, the chief executive officer directly owned 19,561 shares in the company, valued at $471,420.10. This trade represents a 42.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Immunovant Stock Performance

Shares of NASDAQ IMVT remained flat at $24.50 during mid-day trading on Friday. The company had a trading volume of 2,013,045 shares, compared to its average volume of 1,302,727. The stock has a market cap of $4.99 billion, a price-to-earnings ratio of -9.11 and a beta of 0.67. The stock’s fifty day moving average price is $25.78 and its 200 day moving average price is $23.41. Immunovant, Inc. has a 52-week low of $12.72 and a 52-week high of $29.25.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings results on Friday, February 6th. The company reported ($0.61) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.11. During the same period last year, the firm posted ($0.76) EPS. On average, equities research analysts expect that Immunovant, Inc. will post -2.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Wolfe Research upgraded shares of Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 price target on the stock in a report on Tuesday, January 6th. Guggenheim lifted their price objective on shares of Immunovant from $41.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a report on Friday, January 9th. Sanford C. Bernstein started coverage on shares of Immunovant in a research note on Friday, March 20th. They issued a “market perform” rating and a $28.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Immunovant in a report on Tuesday, February 10th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $32.00.

Immunovant News Roundup

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Management highlights brepocitinib program expansion as a strategic response, signaling a shift of R&D and commercial focus toward the oral JAK/TYK2 asset that could partially offset the batoclimab setback; this gives investors a tangible alternative program to watch for future value creation. Immunovant Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
• Neutral Sentiment: Company released additional corporate materials/slideshow discussing the pipeline and Phase 3 update; these materials provide management context but don’t replace the clinical outcomes that move valuation. Monitor upcoming investor calls or detailed data disclosures for clarification. Slideshow: Brepocitinib and Batoclimab Phase III Data Update
• Negative Sentiment: Batoclimab failed to meet primary endpoints in Phase 3 TED trials — multiple outlets report the late‑stage miss and its immediate negative market implications; this reduces the expected near‑term revenue runway from that program and increases execution risk. Reuters: Treatment for eye disease fails late‑stage trial
• Negative Sentiment: CEO Eric Venker sold 14,229 shares at an average $24.10 (a ~42% reduction in his holdings), a disclosure that can amplify negative sentiment after the clinical setback; insiders selling after disappointing news may concern some investors. SEC Form 4: Insider Sale

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Geneos Wealth Management Inc. acquired a new stake in shares of Immunovant during the 4th quarter valued at about $25,000. Strs Ohio purchased a new position in shares of Immunovant in the 1st quarter valued at about $27,000. Aster Capital Management DIFC Ltd acquired a new position in Immunovant in the 3rd quarter worth about $33,000. PNC Financial Services Group Inc. raised its holdings in Immunovant by 138.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company’s stock worth $46,000 after purchasing an additional 1,646 shares during the period. Finally, Quarry LP boosted its position in Immunovant by 94.9% during the fourth quarter. Quarry LP now owns 3,000 shares of the company’s stock worth $76,000 after purchasing an additional 1,461 shares in the last quarter. Institutional investors and hedge funds own 47.08% of the company’s stock.

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.